MPLT
MapLight Therapeutics, Inc.
NasdaqGSUSDEQUITY
DELAYED
Last price
11.50
▲ 0.27 (2.40%)
MARKET · —
Price
Too many bars for candle bodies at this width — showing high/low range per bar. Zoom in or pick a shorter range.
Open
11.41
Prev close
11.23
Day high
11.61
Day low
11.07
Volume
435.20K
Market cap
—
P/E (TTM)
—
52W range
9.10 – 40.43
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Trailing performance
Returnvs SPY
1W
-4.60%
-3.2%
1M
-68.18%
-71.9%
3M
-61.71%
-64.8%
6M
-37.30%
-48.4%
YTD
-36.18%
-48.5%
1Y
—
-20.0%
3Y
—
-74.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | YoY |
|---|---|---|---|
| Total revenue | $0 | — | — |
| Operating revenue | $0 | — | — |
| Research & development | $138.35M | — | — |
| Selling, general & admin | $30.73M | — | — |
| Total operating expense | $169.08M | — | — |
| Operating income | -$169.08M | — | — |
| Net interest income | $5.52M | — | — |
| Pre-tax income | -$161.15M | — | — |
| Net income | -$161.15M | — | — |
| Net income to common | -$161.15M | — | — |
| Basic EPS | -18.56 | -2.96 | -526.2% |
| Diluted EPS | -18.56 | -2.96 | -526.2% |
| EBIT | -$169.08M | — | — |
| EBITDA | -$168.50M | — | — |
| Basic shares | 8.68M | 26.18M | -66.8% |
| Diluted shares | 8.68M | 26.18M | -66.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $46.73M | — | — | — | — |
| Cash & short-term investments | $305.10M | — | — | — | — |
| Total current assets | $324.67M | — | — | — | — |
| Property, plant & equipment | $6.58M | — | — | — | — |
| Total assets | $479.51M | — | — | — | — |
| Total current liabilities | $16.23M | — | — | — | — |
| Total debt | $5.80M | — | — | — | — |
| Total liabilities | $21.14M | $21.72M | $20.13M | $18.52M | -2.7% |
| Retained earnings | -$360.52M | — | — | — | — |
| Shareholder equity | $458.37M | $115.19M | $71.28M | $20.87M | +297.9% |
| Working capital | $308.44M | — | — | — | — |
| Net tangible assets | $458.37M | $115.19M | $71.28M | $20.87M | +297.9% |
| Shares issued | 44.02M | — | — | — | — |
| Line item | 2025 | YoY |
|---|---|---|
| Net income | -$161.15M | |
| Depreciation & amortisation | $578.00K | |
| Stock-based compensation | $36.01M | |
| Change in working capital | -$12.84M | |
| Operating cash flow | -$138.14M | |
| Capital expenditure | -$473.00K | |
| Investing cash flow | -$323.21M | |
| Financing cash flow | $469.82M | |
| Free cash flow | -$138.61M | |
| End cash position | $46.94M |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | — | $0 | — |
| Operating revenue | $0 | $0 | $0 | — | $0 | — |
| Research & development | $53.68M | $64.62M | $27.09M | $19.79M | $20.71M | -16.9% |
| Selling, general & admin | $10.82M | $18.75M | $4.40M | — | $2.06M | -42.3% |
| Total operating expense | $64.50M | $83.38M | $31.50M | $23.54M | $22.78M | -22.6% |
| Operating income | -$64.50M | -$83.38M | -$31.50M | -$23.54M | -$22.78M | +22.6% |
| Net interest income | $2.47M | $2.47M | $1.55M | — | $899.00K | +0.1% |
| Pre-tax income | -$60.67M | -$79.55M | -$29.42M | -$22.34M | -$21.23M | +23.7% |
| Net income | -$60.67M | -$79.55M | -$29.42M | -$22.34M | -$21.23M | +23.7% |
| Net income to common | -$60.67M | -$79.55M | -$29.42M | -$22.34M | -$21.23M | +23.7% |
| Basic EPS | -1.34 | -2.47 | -0.71 | -0.54 | — | +45.7% |
| Diluted EPS | -1.34 | -2.47 | -0.71 | -0.54 | — | +45.7% |
| EBIT | -$64.50M | -$83.38M | -$31.50M | -$23.54M | -$22.78M | +22.6% |
| EBITDA | -$64.34M | -$83.24M | -$31.36M | -$23.38M | -$22.58M | +22.7% |
| Basic shares | 45.21M | 32.15M | 41.43M | — | — | +40.6% |
| Diluted shares | 45.21M | 32.15M | 41.43M | — | — | +40.6% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $55.71M | $46.73M | $64.15M | — | — | $38.25M | +19.2% |
| Cash & short-term investments | $310.11M | $305.10M | $227.17M | — | — | $108.80M | +1.6% |
| Total current assets | $327.23M | $324.67M | $245.31M | — | — | $114.60M | +0.8% |
| Property, plant & equipment | $6.23M | $6.58M | $6.57M | — | — | $7.56M | -5.4% |
| Total assets | $418.79M | $479.51M | $257.22M | — | — | $136.92M | -12.7% |
| Total current liabilities | $14.28M | $16.23M | $18.56M | — | — | $15.92M | -12.0% |
| Total debt | $5.59M | $5.80M | $6.01M | — | — | $6.58M | -3.6% |
| Total liabilities | $18.95M | $21.14M | $23.71M | $20.36M | $18.57M | — | -10.3% |
| Retained earnings | -$421.19M | -$360.52M | -$280.97M | — | — | -$199.37M | -16.8% |
| Shareholder equity | $399.83M | $458.37M | $233.52M | $63.76M | $93.00M | — | -12.8% |
| Working capital | $312.94M | $308.44M | $226.74M | — | — | $98.68M | +1.5% |
| Net tangible assets | $399.83M | $458.37M | $233.52M | $63.76M | $93.00M | — | -12.8% |
| Shares issued | 45.21M | 44.02M | 41.43M | — | — | 41.43M | +2.7% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$60.67M | -$79.55M | -$29.42M | -$22.34M | -$21.23M | +23.7% |
| Depreciation & amortisation | $162.00K | $140.00K | $136.00K | — | $194.00K | +15.7% |
| Stock-based compensation | $9.64M | $35.52M | $125.00K | — | $214.00K | -72.9% |
| Change in working capital | $273.00K | -$1.72M | -$2.39M | -$3.54M | -$523.00K | +115.9% |
| Operating cash flow | -$51.18M | -$46.83M | -$31.79M | — | -$21.49M | -9.3% |
| Capital expenditure | -$24.00K | -$376.00K | -$31.00K | — | -$106.00K | +93.6% |
| Investing cash flow | $67.01M | -$242.55M | -$135.59M | — | $32.39M | +127.6% |
| Financing cash flow | -$6.85M | $271.96M | $198.06M | — | $5.00K | -102.5% |
| Free cash flow | -$51.20M | -$47.20M | -$31.82M | — | -$21.59M | -8.5% |
| End cash position | $55.91M | $46.94M | $64.35M | — | $38.46M | +19.1% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
11.65
-1.31% from price
SMA 20
12.23
-8.37% from price
SMA 50
25.41
-55.89% from price
SMA 100
26.79
-57.07% from price
SMA 200
22.08
-49.23% from price
EMA 12
12.65
-9.07% from price
EMA 26
16.96
-32.20% from price
EMA 50
21.40
-46.26% from price
RSI (14)
29.9
Oversold
MACD (12,26,9)
-4.31
Hist 0.52
ATR (14)
0.95
8.46% of price
Realised vol 30D
387.9%
Annualised
Bollinger upper
14.42
20, 2σ
Bollinger lower
10.05
20, 2σ
50 / 200 cross
Golden
25.41 vs 22.08
Trend bias
Below 200
-49.23%
Risk profile
Beta vs SPY
0.94
Less volatile than market
Correlation to SPY
0.10
Largely independent
Realised vol 30D
387.9%
Annualised
Market vol 1Y
13.2%
SPY, annualised
Max drawdown 1Y
-75.1%
Peak to trough
Max drawdown 5Y
-75.1%
Peak to trough
ATR 14
0.95
8.46% of price
Beta (reported)
—
5Y monthly, from filing
Headlines
AstraZeneca scores in lung cancer; Sandoz inks a China deal
BioPharma Dive · 5d ago
MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
GlobeNewswire · 9d ago
Sector Update: Healthcare Stocks Softer Late Afternoon
MT Newswires · 9d ago
Sector Update: Healthcare Stocks Softer in Afternoon Trading
MT Newswires · 9d ago
MapLight Therapeutics Launching $150 Million Private Placement Financing
MT Newswires · 9d ago
MapLight Therapeutics Announces $150 Million Private Placement Financing
GlobeNewswire · 10d ago
UBS Downgrades MapLight Therapeutics to Neutral From Buy, Adjusts PT to $13 From $52
MT Newswires · 13d ago
MapLight CEO on what investors missed in the biotech’s schizophrenia data
BioPharma Dive · 24d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.